[Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
D000368:Aged; D002230:Carbidopa / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002395:Catecholamines / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000097:blood / Q000134:cerebrospinal fluid / Q000652:urine; D004298:Dopamine / Q000097:blood / Q000134:cerebrospinal fluid / Q000652:urine; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism
D002395:Catecholamines; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D002230:Carbidopa; D004298:Dopamine; D006719:Homovanillic Acid